<DOC>
	<DOCNO>NCT00861731</DOCNO>
	<brief_summary>The purpose study determine whether , patient chronic proteinuric nephropathy dyslipidemia , ezetimibe-simvastatin combine therapy effective statin alone achieve optimum lipid control , translate improvement marker vascular damage . Thirty hypertensive patient stable therapy RAS inhibitor , low-density lipoprotein ( LDL ) cholesterol superior 100 mg/ml , treat three different hypolipidemic regimen : Simvastatin alone ( 40 mg/day ) ezetimibe/simvastatin combine therapy ( 10/20 10/40 mg/day ) .</brief_summary>
	<brief_title>Ezetimibe/Simvastatin Combination Proteinuric Nephropathy</brief_title>
	<detailed_description>Patients chronic kidney disease ( CKD ) increase incidence cardiovascular morbidity mortality . Presence hypertension , lipid abnormality inflammation contribute increase cardiovascular risk . Therefore blood pressure control slow progression CKD towards End Stage Renal Failure ( ESRF ) improve clinical outcome . Instead contribution lipid abnormality still completely understood , mainly dyslipidemia interferes number non-traditional cardiovascular risk factor , particularly activate acute-phase response . In proteinuric patient , dyslipidemia highly atherogenic profile , increase total low-density lipoprotein ( LDL ) cholesterol , triglyceride , lipoprotein ( ) serum level , well decrease HDL cholesterol . Numerous study indicate treatment dyslipidemia statin decrease cardiovascular morbidity mortality . Experimental clinical evidence show statin , addition ameliorate lipid profile , may specific renoprotective property , combine Renin-Angiotensin System ( RAS ) inhibitor therapy , may synergize antiproteinuric effect . Preliminary data also available data combination statin ezetimibe ( EZE ) , cholesterol absorption inhibitor , produce additional decrease LDL cholesterol C-reactive protein level , achieve statin monotherapy . Thus , add potential antinflammatory effect hypolipidemic efficacy , combine therapy may expand renal cardioprotective potentiality . It may also permit reduction statin therapeutic dose improve safety profile . Therefore EZE-statin combination therapy may effective therapeutic option statin alone patient high cardiovascular risk , chronic proteinuric patient .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>age &gt; 18 year LDLcholesterol &gt; 100 mg/dl ( without concomitant hypolipidemic drug ) patient whit high cardiovarscular risk concomitant presence : proteinuric chronic nephropathy define creatinine clearance &gt; 20 ml/min/1,73 m2 combine urinary protein excretion rate &gt; 0,3 g/24h , without evidence urinary tract infection overt heart failure ( New York Heart Association class III ) hypertension define systolic diastolic blood pressure &gt; 140 90 mmHg respectively ( less patient concomitant antihypertensive therapy ) previous concomitant treatment steroid , antiinflammatory immunosuppressive agent evidence suspicion renovascular disease , obstructive uropathy , type I diabetes mellitus , vasculitides , history poor tolerance allergy ACEi ATA , statin EZE , drug abuse pregnancy inability fully understand purposes/risks study provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>chronic renal failure</keyword>
	<keyword>proteinuria</keyword>
	<keyword>apolipoprotein</keyword>
	<keyword>c reactive protein</keyword>
</DOC>